B · Normal
On October 26th, Johnson & Johnson announced data that its drug Rybrevant Faspro achieved an objective response rate (ORR) of 77% in the first-line treatment of head and neck squamous cell carcinoma (HNSCC).
U.S. stock trends 🕐 2026-10-26 02:28
#Johnson & Johnson #cell #U.S. stock trends
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On October 26, Jefferies raised its target price for Apple from $263.66 to $270. 10-26 12:53 [Kelun Pharmaceutical Subsidiaries Announced Multiple Innovative Drug Research R 10-26 12:29 [Most of the main domestic futures contracts rose, with methanol and asphalt ris 10-26 11:36 [Apple customer service responds to “iPhone Duo breaks in some channels”: Prices 10-26 10:07 October 26th: U.S. stock futures weakened at the beginning of Asia-Pacific tradi 10-26 06:00 On October 26th, Musk stated that SpaceX will not acquire any new cloud service 10-26 05:07

Comments

0/500
Captcha (click to refresh)
No comments yet